Psychiatric disorders and depression in multiple sclerosis outpatients: Impact of disability and interferon beta therapy

University of Verona, Verona, Veneto, Italy
Neurological Sciences (Impact Factor: 1.45). 11/2005; 26(4):255-62. DOI: 10.1007/s10072-005-0468-8
Source: PubMed


Associations between psychopathology and gender, duration of MS, disability and therapy with beta-interferons were studied in multiple sclerosis (MS) outpatients. A controlled descriptive epidemiological study was carried out in two Italian outpatient MS centres on 50 outpatients with clinically definite relapsing-remitting MS presenting for regular follow-up and 50 healthy controls matched for sex, age and educational level. Subjects were assessed with the Structured Clinical Interview for DSM-IV (SCID I), the Beck Depression Inventory (BDI) and the State Trait Anxiety Inventory (STAI). MS patients reported a higher prevalence of psychiatric disorders (odds ratio 3.17), with 46% (n=23) suffering from major depressive disorder. The risk of suffering from any non-mood psychiatric disorder was also higher in MS patients than in controls (odds ratio 2.67). Risk factors for depression were female sex and severity of disability, but not therapy with interferon beta or longer duration of illness. Disability level, but not therapy with beta-interferons, is a risk factor for depression in MS outpatients. Regular screening for depression in this population is appropriate.

1 Follower
6 Reads
    • "Our results are similar to those described by Beiske et al.; these authors reported anxiety symptoms in 19.3% of patients using the Hopkins Symptom Checklist (HSCL-25) [17]. Moreover, Feinstein and Korostil detected anxiety disorders throughout life in 35.7% of patients with MS using the SCID-I [7]. These differences may be explained by different study populations and different instruments used. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to evaluate the frequency of psychiatric disorders, particularly mood disorders and anxiety in an outpatient sample of patients with multiple sclerosis in Brazil, and correlate the result with sociodemographic and clinical data. Methods: Cross-sectional study, patients evaluated consecutively, for the clinical, demographic, prevalence of psychiatric disorders was used structured interview (MINI), severity of symptoms of depression and anxiety was used Beck inventory. Results: The prevalence of major lifelong depression in this population was 36.6%, and the risk of suicide was high. There was no detectable correlation between depression, degree of disability, or disease duration. Conclusion: The prevalence of mood disorders is high in MS. Depression is an important factor related to the risk of suicide and should be investigated systematically.
  • Source
    • "The cooccurrence of autoimmune diseases has also been described. For instance, case-control studies showed that BD patients present high frequency of systemic lupus erythematosus [13], multiple sclerosis [14] [15], and autoimmune thyroiditis [16]. Recently a cohort study showed that a history of Guillain-Barre syndrome, Crohn's disease, or autoimmune hepatitis was associated with a raised risk of BD [17]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Bipolar disorder (BD) is a severe, chronic, and recurrent psychiatric illness. It has been associated with high prevalence of medical comorbidities and cognitive impairment. Its neurobiology is not completely understood, but recent evidence has shown a wide range of immune changes. Cytokines are proteins involved in the regulation and the orchestration of the immune response. We performed a review on the involvement of cytokines in BD. We also discuss the cytokines involvement in the neuroprogression of BD. It has been demonstrated that increased expression of cytokines in the central nervous system in postmortem studies is in line with the elevated circulating levels of proinflammatory cytokines in BD patients. The proinflammatory profile and the immune imbalance in BD might be regarded as potential targets to the development of new therapeutic strategies.
    Neural Plasticity 09/2014; 2014:360481. DOI:10.1155/2014/360481 · 3.58 Impact Factor
  • Source
    • "Author's personal copy depression symptoms at T2 were depression symptoms at T1 and presence of MS DMT at T2. Though some research has indicated an increased risk for depression with interferon types of DMT (Mohr et al., 1999), this finding has not been consistent (Galeazzi et al., 2005), and the most recent research suggests such treatments may affect mood but are unlikely to cause clinical depression (Patten et al. 2008). Information about the date of initiation of DMT and timing of BDI-FS administration within the course of medical treatment were not collected as part of the chart review; thus, we are unable to draw conclusions about the impact of DMT on mood long-term in the present sample. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Depression, a frequent concomitant disorder in multiple sclerosis (MS), can impact MS treatment adherence and quality of life. Depression screening in MS care settings may facilitate needed intervention when providers are responsive to screening findings. This study sought to examine the relationship between depression screening results and provider depression treatment recommendations documented in the medical records of 283 patients receiving care in an integrated MS clinic. Forty-six percent of patients screening positive for depression received a treatment recommendation; females, those with past mental health diagnoses, on psychotropic medications, and those with higher symptom severity were more likely to receive a treatment recommendation. On subsequent screenings, patients reported fewer depressive symptoms regardless of whether a formal treatment recommendation was documented. These findings suggest that while depression screening does lead to depression related intervention in many cases, more research is necessary to determine who is most likely to benefit and under what conditions.
    Journal of Clinical Psychology in Medical Settings 09/2014; 21(4). DOI:10.1007/s10880-014-9409-0 · 1.49 Impact Factor
Show more